← Back to patent-cliff list
Pimecrolimus
Tier C — Watch / tradePimecrolimus
Novartis
Originator
2001
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Calcineurin, FKBP1A
Brand：Elidel
Indications (approved)：Eczema, Atopic dermatitis
Regional status
US
Approved
2001-12-13
EU
No progress
2001-12-01
China
Approved
2005-09-29
Japan
No progress
2004-05-01
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Pimecrolimus?
Approved indications include: Eczema, Atopic dermatitis.
When does the Pimecrolimus patent expire?
No public expiry year is available for Pimecrolimus yet; this page updates once verified.
How do I get a quote for Pimecrolimus intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27